Pyxis Oncology (PYXS) stock
Follow PYXS's trial news. Members get an alert when Pyxis Oncology files news, and see its trials, share raises, and its CEO's filings.
What's next for PYXS, and how long its cash lasts
From Pyxis Oncology’s SEC filings and ClinicalTrials.gov: the company’s own words and the arithmetic, not a forecast. Companies often miss their own dates.
Next step the company has named
Cash runway
About 1 quarter
FDA dates in the next 60 days
Decision dates and advisory committee meetings the companies have announced in their own filings, soonest first.
Why PYXS scores 0
Below AverageChoppy, 4 of 14 checks firingWhat the Quality Score means
- +4Momentum traits 4 of 14 firing right now, one point each
- −3News Dilutive offering
- Long-term trend adds
- Run-up adds
- Size subtracts
- Profit subtracts
- Volatility subtracts
What's next
Expected to report Mon Nov 2, before the open
After its last 4 reports it closed -4.3% on average, higher 1 of 4 times.
What would turn PYXS's score around: 5 things, for members
Here is what members see.
Every stock gets a card like this one, and a page with its price in real time, every line of its score, the chart, and its filings.
PYXS has 4 of 14 checks firing
One per group is shown here.
How PYXS ranks in Biotech
PYXS is #141 of 276 by Quality Score. The top three are shown with their scores, and the rest by name.
ABCL10/1420
EXEL9/1419
RGEN7/1419
ONCOpen for its score
PBYIOpen for its score
PYXS4/140
When does PYXS report, and what happens after?
Expected to report Mon Nov 2, before the open (in 33 days). Not yet confirmed by the company.
| Reported | When | Gap | Reaction | 5 sessions |
|---|---|---|---|---|
| Aug 13, 2026Before open | Before open | -7.2% | -5.3% | +6.0% |
| May 14, 2026Before open | Before open | +1.1% | -15.7% | -23.7% |
| Mar 23, 2026Before open | Before open | +2.0% | -3.4% | -10.9% |
| Nov 3, 2025Before open | Before open | -2.3% | +7.0% | +9.8% |
About Pyxis Oncology
Pyxis Oncology Inc is a clinical-stage oncology company focused on developing therapies for patients with solid tumors, with an initial emphasis on head and neck squamous cell carcinoma. Its product candidate, micvotabart pelidotin (MICVO, formerly PYX-201), is an investigational antibody-drug conjugate that targets extradomain-B fibronectin (EDB+FN), a component of the tumor extracellular matrix that is expressed in tumors and minimally present in normal tissues. MICVO consists of a fully human monoclonal antibody linked to a microtubule inhibitor payload, designed to bind within the tumor microenvironment and release its payload to kill cancer cells directly, affect nearby cells through a bystander effect, and induce immunogenic cell death, supporting enhanced anti-tumor activity.
Every line of the score, on every stock.
- Real-time prices, no delay
- Every line of PYXS's score, with the points and the reason
- All 14 checks on PYXS and on all 2,952 stocks
- Every stock ranked, with the chart
- Every filing, and optional alerts on PYXS
Straight Answers.
Are the prices delayed?
Only on the public pages, which run at least 15 minutes behind. Members, trial included, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Where does the data come from?
Daily bars, quotes, reference data, headlines, and short interest come from Massive, formerly Polygon, a licensed market data vendor. The age of the quotes is shown at the top of every page. Insider trades, notable holders and profits come straight from the SEC. That means Form 4 filings, 13F filings and XBRL financial data on EDGAR. Government filings come from the public STOCK Act and Office of Government Ethics disclosures. The market-wide headlines on the market line also come from the public headline feeds CNBC, MarketWatch and Yahoo Finance publish, shown as the headline, the source and a link to the article. Splits, dividends, and the financial statements on each ticker page come from the vendor's reference data. The 8-K filings on EDGAR are read for the items that move a price. Five years of history is loaded for every stock. So the 200-day and 52-week traits rest on real history. Options flow is not part of the product.
What does it cost?
Nothing for the first 8 days. After that, one plan with everything in it, only if you choose to subscribe: $29 a month, $69 for three months, or $249 a year. Payments go through Stripe, so Breakaway never sees your card.
Is this investment advice?
No. It is a screening tool that scores stocks on the chart, the company's own results, and the news and filings. It does not know your situation and it is not a recommendation to buy or sell anything. Please do your own research.